Spectrum Pharma

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectrum Pharmaceuticals is a biopharmaceutical company that focuses on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus on oncology. It has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development.

SAN DIEGO--(BUSINESS WIRE)-- #SPPIstock--The suit alleges defendants issued false statements concerning Spectrum business and prospects, resulting in its stock trading at inflated prices.

SPPI ALERT: Investors With Substantial Losses Have Opportunity to Lead the Spectrum Pharmaceuticals, Inc. Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 1, 2021. SO WHAT: If you purchased Spectrum Pharmaceuticals securi

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SPPI

Boston, Massachusetts--(Newsfile Corp. - September 1, 2021) - Block & Leviton announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sppi.What is this all about?Biotechnology company, Spectrum Pharmaceuticals, announced today before the market opened, that the...

LAWSUIT FILED: SPECTRUM PHARMACEUTICALS Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

NEW YORK, Aug. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action Against Spectrum Pharmaceuticals, Inc and Certain Officers - SPPI

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q2 2021 Results - Earnings Call Transcript

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals (SPPI), a biopharma company focused on novel and targeted oncology therapies, reports results for 2Q2021 and a corp update.

Spectrum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Update

SPPI received a surprise CRL for rolontis.

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

SAN DIEGO, Aug. 6, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI). On August 6, 2021, Spectrum announced the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration regarding the Company's Biologics License Application for ROLONTIS®.

(SPPI) Alert: Did You Lose Money on Your Investment? Contact Johnson Fistel Regarding Investigation

The company received a thumbs-down from the FDA for its lead pipeline candidate.

Why Spectrum Pharmaceuticals Stock Is Crashing Today

Boston, Massachusetts--(Newsfile Corp. - August 6, 2021) - Block & Leviton is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for potential securities law violations. Investors who have lost money in their Spectrum Pharmaceuticals investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sppi.What is this all about?Spectrum announced today that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration regarding...

SPECTRUM PHARMACEUTICALS INVESTIGATION: Block & Leviton Is Investigating Spectrum Pharmaceuticals For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) has received an FDA Complete Response Letter (CRL) regarding its marketing application for Rolontis (eflapegrastim) for neutropenia (low count of a type of white blood cell) in patients receiving myelosuppressive anti-cancer drugs. The CRL cited deficiencies related to manufacturing and indicated that a reinspection would be necessary.

Spectrum Pharma Stock Craters As FDA Slaps Response Letter For Its Neutropenia Candidate

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals (NasdaqGS: SPPI), today announced receipt of a CRL from the U.S. FDA regarding its BLA for ROLONTIS® (eflapegrastim).

Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for ROLONTIS® (eflapegrastim)

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals (SPPI), will host a conf. call to discuss 2Q 2021 financial results and provide a corp update on 8.12.21 at 4:30 p.m. ET.

Spectrum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Corporate Update

The FDA completed the inspection of Hanmi's Korean facility almost a month ago.

Spectrum's Big Approval: Any Day Now

Investors need to pay close attention to for Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.

Implied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock Options

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals today presented an e-poster on poziotinib CNS activity in patients with NSCLC EGFR or HER2 exon 20 mutations at ASCO.

Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the ZENITH20 Clinical Trial at 2021 ASCO Annual Meeting

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals announces that the FDA is “on site” for the ROLONTIS® (eflapegrastim) manufacturing facility inspection.

Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals to present poster for poziotinib in brain mets at upcoming ASCO Annual Meeting beginning on June 4 2021.

Spectrum Pharmaceuticals to Present Data for Poziotinib in Patients with Brain Metastases at the Upcoming 2021 ASCO Annual Meeting

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals (SPPI) to participate in the Jefferies and JMP Securities investor conferences in June.

Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences in June

Rolontis approval was delayed due to Covid-19 and the FDA's inability to inspect its Korean manufacturing facility. The FDA plans to inspect the Hanmi facility this month.

Spectrum Pharmaceuticals: Rolontis Korean Facility Inspection Presents Opportunity

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q1 2021 Results - Earnings Call Transcript

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update

Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update

HENDERSON, Nev.--(BUSINESS WIRE)---- $sppi--Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update

Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #AACR--Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021

Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #AACR--Spectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing Data

News for Spectrum Pharma Stock (SPPI)